Most Recent
Unanimously dismissing an appeal by thoroughbred breeding and horseracing giant Godolphin, the High Court has ruled on the proper construction of a tax exemption for rural land in NSW.
Drug giant Pfizer has blasted Samsung Bioepis' “fishing expedition” in its suit alleging infringement of the patent for its blockbuster arthritis drug Enbrel, telling the court the Korean biotech should not be allowed to dig for new grounds of invalidity.
Fortescue has brought legal action against start-up Element Zero and three former employees, alleging “industrial scale misuse” of the Western Australian mining company's confidential information.
The co-owners of Pacific Werribee shopping centre in Victoria have largely won their bid for insurance documents as they weigh a second case against collapsed construction company Probuild, allegedly worth up to $335 million.
The online safety watchdog has dropped her Federal Court action seeking to force X to put a worldwide block on graphic footage of the April stabbing of a religious leader at Wakeley, following a judge's decision not to maintain an injunction against the social media platform.
After an 18-month investigation, the Office of the Australian Information Commissioner has lodged civil penalty proceedings against Medibank over its October 2022 data breach, accusing the health insurer of breaching the Privacy Act.
A judge has thrown out a self-represented customer’s lawsuit against non-bank lender Latitude Financial after he defaulted on court orders and refused to join tech giants DXC Technology and Crowdstrike to his case over a cyberattack that compromised 14 million customer records.
MinterEllison’s Perth office has welcomed a new energy and resources expert from Dentons, fleshing out the firm's Western Australian capabilities.
The Australian Energy Regulator has secured a $2.75 million penalty in a case against oil and gas company Santos alleging record-keeping failures in breach of the National Gas Rules.
A judge has upheld Neurim Pharmaceutical’s claim for additional damages against two generic drug companies found to have infringed its patent for insomnia drug Circadin, despite the company's failure to comply with an earlier ruling.